BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-698@pharmaconomics
DTSTAMP:20260707T050151Z
DTSTART;VALUE=DATE:20260226
DTEND;VALUE=DATE:20260227
SUMMARY:URGN Phase 3 — UGN-103
DESCRIPTION:Phase 3 trial results for UGN-103 in recurrent LG-IR-NMIBC are due Feb 26\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm\n\nTrack it: https://www.pharmaconomics.com/e/698
URL:https://www.pharmaconomics.com/e/698
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:URGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR